SCHEDULE 13G/A 0000315066-19-001726 0000315066 XXXXXXXX LIVE 10 CLASS A COMMON STOCK 06/30/2025 0001770787 10x Genomics, Inc. 88025U109 6230 STONERIDGE MALL ROAD 6230 STONERIDGE MALL ROAD PLEASANTON CA 94588 Rule 13d-1(b) FMR LLC DE 9806070.00 0.00 9839175.62 0.00 9839175.62 8.8 HC Abigail P. Johnson X1 0.00 0.00 9839175.62 0.00 9839175.62 8.8 IN 10x Genomics, Inc. 6230 STONERIDGE MALL ROAD, 6230 STONERIDGE MALL ROAD, PLEASANTON, CALIFORNIA, 94588. FMR LLC 245 Summer Street, Boston, Massachusetts 02210 Not applicable N HC 9,839,175.62* *892,772 of the shares of Class A Common Stock of 10X GENOMICS INC reported as being beneficially owned by the reporting persons at June 30, 2025, are included in this Schedule 13G because the Reporting persons are deemed to beneficially own such shares as a result of the direct ownership of 892,772 shares of Class B Common Stock of 10X GENOMICS INC by investment companies advised by Fidelity Management & Research Company LLC, FIAM LLC, Fidelity Institutional Asset Management Trust Company, Fidelity Management Trust Company, and Strategic Advisers LLC, indirect wholly-owned subsidiaries of FMR LLC as of such date, which shares of Class B Common Stock are convertible into shares of Class A Common Stock at the election of the holder at an exchange rate of 1:1. Such shares of Class B Common Stock represent 7.4144% of the outstanding Class B Common Stock. Assuming the conversion of all outstanding shares of Class B Common Stock into Class A Common Stock, the 9,839,175.620 shares of Class A Common Stock reported as being beneficially owned by the reporting persons in this Schedule 13G would represent 7.9906% of the outstanding Class A Common Stock. 8.8% Please see the responses to Items 5 and 6 on the cover page. 0.00 9,839,175.62* *892,772 of the shares of Class A Common Stock of 10X GENOMICS INC reported as being beneficially owned by the reporting persons at June 30, 2025, are included in this Schedule 13G because the Reporting persons are deemed to beneficially own such shares as a result of the direct ownership of 892,772 shares of Class B Common Stock of 10X GENOMICS INC by investment companies advised by Fidelity Management & Research Company LLC, FIAM LLC, Fidelity Institutional Asset Management Trust Company, Fidelity Management Trust Company, and Strategic Advisers LLC, indirect wholly-owned subsidiaries of FMR LLC as of such date, which shares of Class B Common Stock are convertible into shares of Class A Common Stock at the election of the holder at an exchange rate of 1:1. Such shares of Class B Common Stock represent 7.4144% of the outstanding Class B Common Stock. Assuming the conversion of all outstanding shares of Class B Common Stock into Class A Common Stock, the 9,839,175.620 shares of Class A Common Stock reported as being beneficially owned by the reporting persons in this Schedule 13G would represent 7.9906% of the outstanding Class A Common Stock. 0.00 Y N One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the CLASS A COMMON STOCK of 10X GENOMICS INC. No one other person's interest in the CLASS A COMMON STOCK of 10X GENOMICS INC is more than five percent of the total outstanding CLASS A COMMON STOCK. N See attached Exhibit 99. N Not applicable. N Not applicable. N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11. Please see Exhibit 99 for 13d-1(k) (1) agreement. FMR LLC Richard Bourgelas 08/05/2025 Abigail P. Johnson Richard Bourgelas 08/05/2025 *This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on August 8, 2023, accession number: 0000315066-23-002397.